IGN Stock Overview
Inno-Gene S.A. provides genetic diagnostic solutions in Poland. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
HyEnergy S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | zł2.90 |
52 Week High | zł5.60 |
52 Week Low | zł1.65 |
Beta | 1.13 |
11 Month Change | -23.08% |
3 Month Change | -19.44% |
1 Year Change | 0% |
33 Year Change | -67.42% |
5 Year Change | 36.79% |
Change since IPO | -32.56% |
Recent News & Updates
Recent updates
Here's Why We Think Inno-Gene (WSE:IGN) Might Deserve Your Attention Today
Jul 25Here's Why We Think Inno-Gene (WSE:IGN) Is Well Worth Watching
Apr 05Here's Why I Think Inno-Gene (WSE:IGN) Is An Interesting Stock
Dec 28Should You Be Adding Inno-Gene (WSE:IGN) To Your Watchlist Today?
Aug 28We Wouldn't Rely On Inno-Gene's (WSE:IGN) Statutory Earnings As A Guide
Feb 17Shareholder Returns
IGN | PL Life Sciences | PL Market | |
---|---|---|---|
7D | -11.9% | 0.3% | 1.1% |
1Y | 0% | -18.8% | -0.5% |
Return vs Industry: IGN exceeded the Polish Life Sciences industry which returned -18.8% over the past year.
Return vs Market: IGN matched the Polish Market which returned -0.5% over the past year.
Price Volatility
IGN volatility | |
---|---|
IGN Average Weekly Movement | 21.2% |
Life Sciences Industry Average Movement | 6.6% |
Market Average Movement | 4.9% |
10% most volatile stocks in PL Market | 8.5% |
10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: IGN's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: IGN's weekly volatility has increased from 15% to 21% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 8 | n/a | www.inno-gene.pl |
Inno-Gene S.A. provides genetic diagnostic solutions in Poland. It is involved in the research and diagnostic center implementation; and the provision of technologies in the field of DNA analysis. The company also develops and implements diagnostic algorithm for prevention and personalization of treatment of HPV-dependent solid tumors.
HyEnergy S.A. Fundamentals Summary
IGN fundamental statistics | |
---|---|
Market cap | zł104.10m |
Earnings (TTM) | -zł6.22m |
Revenue (TTM) | zł373.00k |
261.1x
P/S Ratio-15.6x
P/E RatioIs IGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IGN income statement (TTM) | |
---|---|
Revenue | zł373.00k |
Cost of Revenue | zł683.00k |
Gross Profit | -zł310.00k |
Other Expenses | zł5.92m |
Earnings | -zł6.22m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.19 |
Gross Margin | -83.11% |
Net Profit Margin | -1,668.90% |
Debt/Equity Ratio | 1.1% |
How did IGN perform over the long term?
See historical performance and comparison